Who we are

Onechain Immunotherapeutics is a clinical stage biotech company based in Barcelona (Spain) and focused in the development of CAR T therapies for the treatment of oncological diseases.

Our lead program is a novel and selective CAR T therapy against CD1a (OC-1) for the treatment of refractory/relapsed patients with cortical T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (co T-ALL), a T-ALL subgroup without many options to date. OC-1 demonstrated strong preclinical safety and efficacy and is currently under evaluation in a phase 1 clinical trial to assess the safety and efficacy of the therapy (CARxALL clinical trial).

OC-1 has been granted Orphan Drug Designation for ALL by the EMA in 2021.


To create a better, healthier world for people with cancer.


To discover, develop and deliver innovative therapeutics for patients suffering from oncological diseases.

Core Values

Integrity Doing What’s Right
Teamwork Working Together
Accountability Taking Personal Responsibility
Excellence Being Your Best